0
PFE25.680USD
-0.590-2.25%
收盘 10/08, 16:00（美东）报价延迟15分钟
145.99B总市值
13.58市盈率 TTM
关于 0 公司
辉瑞公司是一家以研究为基础的全球生物制药公司。该公司在全球范围内从事生物制药产品的发现、开发、制造、营销、销售和分销。其生物制药部门从事以科学为基础的生物制药业务。其生物制药部门包括辉瑞肿瘤部门、辉瑞美国商业部门和辉瑞国际商业部门。其产品类别包括肿瘤、初级保健和专科护理。其肿瘤产品包括 Ibrance、Xtandi、Inlyta、Bosulif、Lorbrena、Braftovi、Mektovi、Padcev、Adcetris、Talzenna、Tukysa、Elrexfio 和 Tivdak。其初级保健产品包括 Eliquis、Nurtec ODT/Vydura、Comirnaty、Prevnar 家族、Abrysvo、FSME/IMMUN-TicoVac、Paxlovid 和 Lucira by Pfizer。其专科护理产品包括 Xeljanz、Enbrel（美国和加拿大以外）、Inflectra、Cibinqo、Litfulo、Vyndaqel 系列、Genotropin、Sulperazon、Zavicefta、Medrol 和 Panzyga。
0简介
公司代码PFE
公司名称Pfizer Inc
上市日期Jan 17, 1944
CEODr. Albert Bourla, Ph.D.
员工数量81000
证券类型Ordinary Share
年结日Jan 17
公司地址66 Hudson Boulevard East
城市NEW YORK
上市交易所NYSE Consolidated
国家United States of America
邮编10001-2192
电话12127332323
网址https://www.pfizer.com/
公司代码PFE
上市日期Jan 17, 1944
CEODr. Albert Bourla, Ph.D.
0公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
Mr. Aamir Malik
Mr. Aamir Malik
Executive Vice President, Chief US Commercial Officer
Executive Vice President, Chief US Commercial Officer
29.55K
+7800.53%
Ms. Payal Sahni
Ms. Payal Sahni
Executive Vice President, Chief People Experience Officer
Executive Vice President, Chief People Experience Officer
24.85K
+6.62%
Mr. Cyrus Taraporevala
Mr. Cyrus Taraporevala
Independent Director
Independent Director
10.00K
--
Dr. Scott Gottlieb, M.D.
Dr. Scott Gottlieb, M.D.
Independent Director
Independent Director
10.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Albert Bourla, Ph.D.
Dr. Albert Bourla, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
372.89K
+10.54%
Mr. Douglas M. Lankler
Mr. Douglas M. Lankler
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
161.04K
+8.26%
Ms. Sally Susman
Ms. Sally Susman
Executive Vice President, Chief Corporate Affairs Officer
Executive Vice President, Chief Corporate Affairs Officer
95.94K
+8.23%
Mr. Michael (Ike) Mcdermott
Mr. Michael (Ike) Mcdermott
Executive Vice President, Chief Global Supply Officer
Executive Vice President, Chief Global Supply Officer
70.77K
-0.78%
Mr. Ronald E. Blaylock
Mr. Ronald E. Blaylock
Independent Director
Independent Director
32.46K
+149.67%
Ms. Lidia L. Fonseca
Ms. Lidia L. Fonseca
Executive Vice President, Chief Digital and Technology Officer
Executive Vice President, Chief Digital and Technology Officer
30.96K
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
其他
7.52B
51.29%
地区USD
名称
营收
占比
United States
8.89B
60.70%
Developed Markets
3.39B
23.16%
Emerging Markets
2.37B
16.15%
业务
地区
业务USD
名称
营收
占比
Eliquis alliance revenues and direct sales
2.00B
13.67%
Vyndaqel family
1.61B
11.02%
Prevnar family
1.38B
9.44%
All other Hospital
1.09B
7.42%
Oncology-Ibrance
1.05B
7.16%
其他
7.52B
51.29%
股东统计
更新时间: 8月15日 周五
更新时间: 8月15日 周五
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
其他
76.48%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.33%
State Street Global Advisors (US)
5.21%
BlackRock Institutional Trust Company, N.A.
5.08%
Geode Capital Management, L.L.C.
2.24%
Norges Bank Investment Management (NBIM)
1.65%
其他
76.48%
股东类型
持股股东
占比
Investment Advisor
32.83%
Investment Advisor/Hedge Fund
22.82%
Research Firm
3.11%
Pension Fund
2.25%
Bank and Trust
1.84%
Sovereign Wealth Fund
1.75%
Hedge Fund
1.27%
Insurance Company
1.24%
Holding Company
0.05%
其他
32.83%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
4787
3.82B
67.19%
-100.74M
2025Q2
4945
3.85B
67.75%
-89.09M
2025Q1
5074
3.86B
67.90%
-51.97M
2024Q4
5153
3.84B
67.74%
-83.26M
2024Q3
5005
3.85B
67.99%
-51.77M
2024Q2
5026
3.84B
67.75%
-120.77M
2024Q1
5032
3.89B
68.71%
-120.39M
2023Q4
5089
3.97B
70.25%
-96.67M
2023Q3
4952
4.00B
70.89%
-71.80M
2023Q2
4962
4.02B
71.16%
-62.35M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
530.68M
9.33%
+10.10M
+1.94%
Jun 30, 2025
State Street Global Advisors (US)
296.30M
5.21%
-669.22K
-0.23%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
288.89M
5.08%
-2.65M
-0.91%
Jun 30, 2025
Geode Capital Management, L.L.C.
127.47M
2.24%
+1.82M
+1.45%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
93.65M
1.65%
+5.87M
+6.68%
Jun 30, 2025
Wellington Management Company, LLP
77.00M
1.35%
-26.49M
-25.60%
Jun 30, 2025
MFS Investment Management
72.76M
1.28%
-276.04K
-0.38%
Jun 30, 2025
State Farm Insurance Companies
57.59M
1.01%
-158.70K
-0.27%
Jun 30, 2025
BlackRock Asset Management Ireland Limited
54.65M
0.96%
+4.18M
+8.29%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
49.17M
0.86%
+1.14M
+2.36%
Jun 30, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
Franklin US Dividend Booster Index ETF
128.98%
First Trust NASDAQ Pharmaceuticals ETF
7.17%
First Trust Morningstar Dividend Leaders Index Fund
6.24%
Amplify Weight Loss Drug & Treatment ETF
5.07%
Coastal Compass 100 ETF
4.82%
Invesco Pharmaceuticals ETF
4.82%
WBI Power Factor High Dividend ETF
4.75%
LSV Disciplined Value ETF
4.68%
Vaneck Durable High Dividend ETF
4.38%
iShares U.S. Pharmaceuticals ETF
4.28%
查看更多
Franklin US Dividend Booster Index ETF
占比128.98%
First Trust NASDAQ Pharmaceuticals ETF
占比7.17%
First Trust Morningstar Dividend Leaders Index Fund
占比6.24%
Amplify Weight Loss Drug & Treatment ETF
占比5.07%
Coastal Compass 100 ETF
占比4.82%
Invesco Pharmaceuticals ETF
占比4.82%
WBI Power Factor High Dividend ETF
占比4.75%
LSV Disciplined Value ETF
占比4.68%
Vaneck Durable High Dividend ETF
占比4.38%
iShares U.S. Pharmaceuticals ETF
占比4.28%
分红派息
近5年累计派现
44.91B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Dec 12, 2024
PFE.NB Interim Cash Dividend of gross USD 0.43 paid on Mar 07, 2025 going ex on Jan 24, 2025
Jan 24, 2025
Mar 07, 2025
Jan 24, 2025
Oct 09, 2024
PFE.NB Final Cash Dividend of gross USD 0.42 paid on Dec 02, 2024 going ex on Nov 08, 2024
Nov 08, 2024
Dec 02, 2024
Nov 08, 2024
Jun 26, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Sep 03, 2024 going ex on Jul 26, 2024
Jul 26, 2024
Sep 03, 2024
Jul 26, 2024
Apr 24, 2024
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Jun 14, 2024 going ex on May 09, 2024
May 10, 2024
Jun 14, 2024
May 09, 2024
Dec 14, 2023
PFE.NB Interim Cash Dividend of gross USD 0.42 paid on Mar 01, 2024 going ex on Jan 25, 2024
Jan 26, 2024
Mar 01, 2024
Jan 25, 2024
Oct 04, 2023
PFE.NB Final Cash Dividend of gross USD 0.41 paid on Dec 04, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Dec 04, 2023
Nov 09, 2023
Jun 22, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Sep 05, 2023 going ex on Jul 27, 2023
Jul 28, 2023
Sep 05, 2023
Jul 27, 2023
Apr 26, 2023
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Jun 09, 2023 going ex on May 11, 2023
May 12, 2023
Jun 09, 2023
May 11, 2023
Dec 09, 2022
PFE.NB Interim Cash Dividend of gross USD 0.41 paid on Mar 03, 2023 going ex on Jan 26, 2023
Jan 27, 2023
Mar 03, 2023
Jan 26, 2023
Sep 22, 2022
PFE.NB Final Cash Dividend of gross USD 0.4 paid on Dec 05, 2022 going ex on Nov 03, 2022
Nov 04, 2022
Dec 05, 2022
Nov 03, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
